<DOC>
	<DOCNO>NCT00652847</DOCNO>
	<brief_summary>To compare percent ( % ) change plasma LDL-C concentration , six week course treatment ezetimibe 10 mg/day co-administered exist statin versus double exist statin dose</brief_summary>
	<brief_title>Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia ( 0653-152 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients With A Diagnosis Of Primary Hypercholesterolemia And Who Are Defined As Being `` High Risk '' ( 10Year Risk Of Coronary Artery Disease &gt; 20 % Based On The Framingham Model Or History Of Diabetes Mellitus Or Any Atherosclerosis Disease ) And Have Not Reached Their Recommended LdlC Target Levels Of 2.5 Mmol/L While On A Statin Alone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>